1. Home
  2. SCYX vs LPSN Comparison

SCYX vs LPSN Comparison

Compare SCYX & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.89

Market Cap

32.6M

Sector

Health Care

ML Signal

HOLD

Logo LivePerson Inc.

LPSN

LivePerson Inc.

HOLD

Current Price

$2.66

Market Cap

32.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
LPSN
Founded
1999
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
32.6M
32.3M
IPO Year
2014
2000

Fundamental Metrics

Financial Performance
Metric
SCYX
LPSN
Price
$0.89
$2.66
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$3.00
N/A
AVG Volume (30 Days)
318.1K
126.2K
Earning Date
03-04-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
61.36
N/A
EPS
N/A
N/A
Revenue
$257,000.00
$249,838,000.00
Revenue This Year
$90.24
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.39
52 Week High
$1.29
$7.54

Technical Indicators

Market Signals
Indicator
SCYX
LPSN
Relative Strength Index (RSI) 61.44 38.62
Support Level $0.68 $2.56
Resistance Level $1.29 $3.43
Average True Range (ATR) 0.06 0.19
MACD 0.01 -0.02
Stochastic Oscillator 72.58 11.13

Price Performance

Historical Comparison
SCYX
LPSN

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.

Share on Social Networks: